

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO. FILING DATE		FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
10/791,309	03/02/2004	Harold Richardson Crews	708-A04-007C 3542		
27317	7590 12/15/2006		EXAM	EXAMINER	
FLEIT KAIN	I GIBBONS GUTM	YANG, NELSON C			
21355 EAST I SUITE 115	DIXIE HIGHWAY		ART UNIT	PAPER NUMBER	
MIAMI, FL	33180		1641		

DATE MAILED: 12/15/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

		Applicati	on No.	Applicant(s)			
Office Action Summary		10/791,3		CREWS ET AL.			
		Examine		Art Unit	-		
		Nelson Y		1641			
The Period for Rep	MAILING DATE of this communication Y	appears on th	e cover sheet with the c	orrespondence ad	dress		
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status							
1)⊠ Respo	onsive to communication(s) filed on	02 March 2004					
	This action is FINAL . 2b) This action is non-final.						
3)☐ Since	nce this application is in condition for allowance except for formal matters, prosecution as to the merits is						
closed	in accordance with the practice und	der <i>Ex parte</i> Q	uayle, 1935 C.D. 11, 45	3 O.G. 213.			
Disposition of	Claims						
4) ⊠ Claim(s) 1-25 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) □ Claim(s) is/are allowed. 6) □ Claim(s) is/are rejected. 7) □ Claim(s) is/are objected to. 8) ⊠ Claim(s) 1-25 are subject to restriction and/or election requirement.							
Application Pa	pers	•					
 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. 							
Priority under	35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 							
Attachment(s)			•				
2) Notice of Dra 3) Information D	erences Cited (PTO-892) ftsperson's Patent Drawing Review (PTO-940) bisclosure Statement(s) (PTO/SB/08) Mail Date	3)	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal P 6) Other:	nte			

Art Unit: 1641

DETAILED ACTION

Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-3, 18-20, drawn to a stromatolysing reagent for use in the determination of at least two leukocyte populations in blood processed through a blood cell analyzer using the Coulter Principle of operation, classified in class 435, subclass 355.
 - II. Claims 4-6, 21-23, drawn to a method of determining leukocytes and hemoglobin in blood using a lysing agent containing an aqueous solution of a tetralkylammonium halide salt, classified in class 435, subclass 153.
 - III. Claims 7-12, drawn to a kit of a lytic reagent system for selective chemical treatment of a whole blood sample comprising the special technical feature of partitioning a whole blood sample into a lysed red cell fraction and a leukocyte fraction by causing rapid and essentially complete hemolysis of red blood cells in the blood sample, classified in class 435, subclass.
 - IV. Claim 13, drawn to a method for identifying classes and subclasses of leukocytes, classified in class 435, subclass 7.24.
 - V. Claims 14-17, drawn to a multi-purpose isotonic diluent reagent, classified in class 423, subclass 179.
 - VI. Claims 24 and 25, drawn to a method of treating a blood sample and lysing with a reagent, classified in class 435, subclass 269.

Art Unit: 1641

2. The inventions are distinct, each from the other because of the following reasons:

Page 3

- 3. Inventions (I, III, V) and (II, IV, VI) are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the reagent and kits of groups I, III, and V can be used for screening for inherited hemoglobin disorders, while the methods of groups II, IV, VI can utilize other stromatolysing reagents and isotonic diluents such as ethyl hexadecyl dimethyl ammonium bromide and a sodium chromate based diluent.
- Inventions I, III, and V are unrelated, independent and distinct inventions. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions have different functions. The invention of group I is directed toward a stromatolysing reagent requiring an aqueous solution of a tetraalkylammonium halide salt, the invention of group III requires saponin and a lytic reagent at a concentration capable of partioning of a whole blood sample into a lysed red cell fraction and a leukocyte fraction by causing rapid and essentially complete hemolysis of red blood cells in the blood sample, while the invention of group V requires an alkyl metal salt.
- 5. Inventions II, IV, and VI are unrelated, independent and distinct. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have

Art Unit: 1641

different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions have different modes of operation. The invention of group II recites a step using a lysing agent containing an aqueous solution of a tetraalkylammonium halide salt, while the invention of group IV recites a step involving the use of an acid compound reagent and the invention of group VI recites a step involving the use of an isotonic diluent.

6. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, and the search required for one group is not required for others, restriction for examination purposes as indicated is proper.

Because these inventions are independent or distinct for the reasons given above and there would be a serious burden on the examiner if restriction is not required because the inventions require a different field of search (see MPEP § 808.02), restriction for examination purposes as indicated is proper.

7. The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier.

Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

Art Unit: 1641

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai, In re Brouwer* and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

8. Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Art Unit: 1641

9. Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Page 6

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Nelson Yang whose telephone number is (571) 272-0826. The examiner can normally be reached on 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long V. Le can be reached on (571)272-0823. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1641

11. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

applications is available through Private PAIR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR

system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would

like assistance from a USPTO Customer Service Representative or access to the automated

information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Nelson Yang Patent Examiner Art Unit 1641

LONG V. LE (2/08/02)
PERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600

Page 7